Is Regnum Corp halal to invest in?

According to Musaffa's Shariah screening methodology, Regnum Corp (RGMP) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Regnum Corp a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Regnum Corp using these criteria to determine its compliance status.

Can Muslims buy shares of Regnum Corp?

Muslim investors may consider investing in Regnum Corp if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Regnum Corp classified as NOT COVERED?

Musaffa determines the Shariah status of Regnum Corp by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Regnum Corp updated?

The Shariah compliance status of Regnum Corp may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Regnum Corp become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Regnum Corp?

You can check the latest Shariah compliance status of Regnum Corp on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Regnum Corp. Stock Analysis RGMP

United States N/A Nano Cap

Regnum Corp. engages in the business of developing and commercializing therapeutics that treat rare and infectious diseases. The company is headquartered in New York City, New York. The company went IPO on 2019-03-15. The firm's primary asset is the commercial rights to leronlimab (PRO 140) in all human immunodeficiency virus (HIV) indications within the United States. Leronlimab is a monoclonal antibody. The target of leronlimab is the immunologic receptor CCR5. Leronlimab prevents certain strains of HIV from using the CCR5 receptor as an entry gateway for healthy cells. The leronlimab antibody belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells. Leronlimab blocks HIV from entering a cell by binding to a molecule called CCR5 referred to as R5 strains, attach as part of HIVs entry into a cell.

Key Statistics of Regnum Corp (RGMP)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$0.00$0.00

Today's Open

$0.00

Volume

P/E Ratio (TTM)

52 Week Range

$0.01$0.80

Market Cap

23.00

Avg. Volume

Dividend Yield

Financial Metrics & Statements of Regnum Corp (RGMP)

FAQ's for Regnum Corp (RGMP)

According to Musaffa’s Shariah screening methodology, Regnum Corp (RGMP) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.